NZ502392A - Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals - Google Patents

Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals

Info

Publication number
NZ502392A
NZ502392A NZ502392A NZ50239298A NZ502392A NZ 502392 A NZ502392 A NZ 502392A NZ 502392 A NZ502392 A NZ 502392A NZ 50239298 A NZ50239298 A NZ 50239298A NZ 502392 A NZ502392 A NZ 502392A
Authority
NZ
New Zealand
Prior art keywords
preparation
binding proteins
interleukin
pharmaceuticals
binding
Prior art date
Application number
NZ502392A
Other languages
English (en)
Inventor
Daniela Novick
Charles Dinarello
Menachem Rubinstein
Soo Hyun Kim
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12155497A external-priority patent/IL121554A0/xx
Priority claimed from IL12163997A external-priority patent/IL121639A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NZ502392A publication Critical patent/NZ502392A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/834—Urine; urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
NZ502392A 1997-08-14 1998-08-13 Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals NZ502392A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IL12155497A IL121554A0 (en) 1997-08-14 1997-08-14 Interleukin-18 binding proteins their preparation and use
IL12163997A IL121639A0 (en) 1997-08-14 1997-08-27 Interleukin-18 binding proteins their preparation and use
IL12186097A IL121860A0 (en) 1997-08-14 1997-09-29 Interleukin-18 binding proteins their preparation and use
IL12213497A IL122134A0 (en) 1997-08-14 1997-11-06 Interleukin-18 binding proteins their preparation and use
IL12546398A IL125463A0 (en) 1997-08-14 1998-07-22 Interleukin-18 binding proteins their preparation and use
PCT/IL1998/000379 WO1999009063A1 (en) 1997-08-14 1998-08-13 Interleukin-18 binding proteins, their preparation and use

Publications (1)

Publication Number Publication Date
NZ502392A true NZ502392A (en) 2002-12-20

Family

ID=27517687

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ502392A NZ502392A (en) 1997-08-14 1998-08-13 Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals

Country Status (28)

Country Link
US (4) US6605280B1 (enExample)
EP (1) EP1003781B1 (enExample)
JP (1) JP4272348B2 (enExample)
KR (1) KR100687388B1 (enExample)
CN (1) CN1243021C (enExample)
AR (2) AR013422A1 (enExample)
AT (1) ATE443719T1 (enExample)
AU (1) AU755794B2 (enExample)
BG (1) BG65519B1 (enExample)
BR (1) BRPI9811940B8 (enExample)
CA (1) CA2298855C (enExample)
CY (1) CY1109664T1 (enExample)
CZ (1) CZ300818B6 (enExample)
DE (2) DE69841175D1 (enExample)
DK (1) DK1003781T3 (enExample)
EA (1) EA003675B1 (enExample)
EE (1) EE05538B1 (enExample)
ES (1) ES2149149T3 (enExample)
HU (1) HU226698B1 (enExample)
IL (5) IL121860A0 (enExample)
NO (1) NO327240B1 (enExample)
NZ (1) NZ502392A (enExample)
PL (1) PL206070B1 (enExample)
PT (1) PT1003781E (enExample)
SI (1) SI1003781T1 (enExample)
SK (1) SK287194B6 (enExample)
UA (1) UA75862C2 (enExample)
WO (1) WO1999009063A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18-BINDING PROTEINS
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
DE60041432D1 (de) * 1999-11-16 2009-03-12 Hayashibara Biochem Lab Antikörper spezifisch für den Interleukin-18 Vorläufer
HUP0300423A3 (en) * 2000-02-10 2008-07-28 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
ATE506959T1 (de) * 2000-02-21 2011-05-15 Merck Serono Sa Verwendung von il-18 inhibitoren
CN1841066B (zh) * 2000-05-05 2012-08-29 默克雪兰诺有限公司 Il-18抑制剂在治疗和/或预防动脉粥样硬化中的应用
AU2005211606B2 (en) * 2000-05-05 2007-02-22 Inserm - Institut National De La Sante Et De La Recherche Medicale Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
CA2435466C (en) * 2001-01-29 2012-04-03 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of heart disease
JP4502580B2 (ja) * 2001-05-16 2010-07-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 敗血症の治療または予防のためのｉｌ−１８阻害剤の使用
UA80396C2 (en) * 2001-05-25 2007-09-25 Ares Trading Sa Use of il-18 inhibitors for treating or traumatic head injury
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
UA78516C2 (en) * 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
WO2003080104A2 (en) * 2002-03-22 2003-10-02 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
CN1909926A (zh) * 2002-10-08 2007-02-07 阿雷斯贸易股份有限公司 能够结合il－18bp和抑制第二细胞因子活性的细胞因子的用途
IL152232A0 (en) * 2002-10-10 2003-05-29 Yeda Res & Dev Promoter to il-18bp, its preparation and use
JP4134166B2 (ja) * 2003-04-30 2008-08-13 独立行政法人科学技術振興機構 ヒト抗ヒトインターロイキン−１８抗体およびその断片、並びにそれらの利用方法
AU2004238524B2 (en) * 2003-05-13 2011-06-23 Merck Serono Sa Active variants of the IL-18 binding protein and medical uses thereof
WO2005049649A1 (en) 2003-11-05 2005-06-02 Ares Trading S.A. Process for the purification of il-18 binding protein
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
CA2545359C (en) * 2003-11-12 2012-11-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for regulation of tumor necrosis factor-alpha
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
ME01218B (me) * 2004-03-01 2013-06-20 Ares Trading Sa Upotreba podloge za ćelijsku strukturu bez sadrzaja seruma za produkciju il-18bp u ćelijama sisara
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
WO2006003134A1 (en) 2004-06-29 2006-01-12 Ares Trading S.A. Process for the purification of il-18 binding protein
ES2370417T3 (es) * 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
RS52192B (sr) * 2005-06-03 2012-10-31 Merck Serono Sa. Upotreba il-18bp izoforma za terapiju i/ili prevenciju neuroloških zapaljenskih bolesti
AU2006256763B2 (en) * 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
CN101003812B (zh) * 2006-01-17 2011-01-05 温州医学院 一种用于制备重组人egf-il18融合蛋白的方法
ES2514495T3 (es) 2006-05-25 2014-10-28 Glaxo Group Limited Anticuerpos humanizados modificados anti-interleucina-18
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
EP2941310A4 (en) * 2013-01-02 2016-08-24 Wilsa Inc METHOD AND DEVICE FOR CONDITIONING LIQUIDS
ES2892923T3 (es) * 2013-09-05 2022-02-07 Ab2 Bio Sa Proteína de unión a IL-18 (IL-18BP) en enfermedades inflamatorias
EP3265807A1 (en) 2015-03-05 2018-01-10 AB2 Bio SA Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
CN117279950B (zh) * 2022-01-28 2025-08-08 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
MX2024011278A (es) * 2022-03-15 2024-09-25 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用
CN114891125B (zh) * 2022-06-16 2023-04-11 广东医科大学 一种长效重组白细胞介素-18结合蛋白及其生产方法与应用
IL321948A (en) 2023-01-06 2025-09-01 Lassen Therapeutics Inc Anti-IL-18 BP antibodies
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
ATE256476T1 (de) 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
JP4094066B2 (ja) 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビター
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
EP0998300A1 (en) 1997-03-18 2000-05-10 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
ES2260841T3 (es) 1997-08-01 2006-11-01 Serono Genetics Institute S.A. Est 5' para proteinas secretadas expresadas en diversos tejidos.
CA2297157A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in testis and other tissues
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
JP4574007B2 (ja) 1998-04-28 2010-11-04 メルク・セローノ・ソシエテ・アノニム ポリオール−ｉｆｎ−ベータ複体
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18-BINDING PROTEINS
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids

Also Published As

Publication number Publication date
HUP0003533A3 (en) 2003-08-28
US6605280B1 (en) 2003-08-12
DE69841175D1 (de) 2009-11-05
US7101689B2 (en) 2006-09-05
SI1003781T1 (sl) 2009-12-31
HUP0003533A2 (hu) 2001-01-29
HU226698B1 (en) 2009-07-28
EA200000216A1 (ru) 2000-08-28
IL134523A (en) 2011-09-27
US8436148B2 (en) 2013-05-07
US20060154294A1 (en) 2006-07-13
NO327240B1 (no) 2009-05-18
BRPI9811940B8 (pt) 2021-07-06
KR20010022900A (ko) 2001-03-26
CA2298855C (en) 2014-05-27
PL206070B1 (pl) 2010-06-30
PL338647A1 (en) 2000-11-06
SK1762000A3 (en) 2000-09-12
NO20000700L (no) 2000-04-14
JP4272348B2 (ja) 2009-06-03
ES2149149T3 (es) 2009-12-01
AR013422A1 (es) 2000-12-27
IL122134A0 (en) 1998-04-05
JP2001514876A (ja) 2001-09-18
BG104149A (bg) 2000-08-31
IL121860A0 (en) 1998-02-22
AU8746098A (en) 1999-03-08
EE200000073A (enExample) 2000-10-16
IL125463A0 (en) 1999-03-12
ATE443719T1 (de) 2009-10-15
AU755794B2 (en) 2002-12-19
EE05538B1 (et) 2012-04-16
HK1028773A1 (en) 2001-03-02
BG65519B1 (bg) 2008-10-31
NO20000700D0 (no) 2000-02-11
SK287194B6 (sk) 2010-03-08
EA003675B1 (ru) 2003-08-28
KR100687388B1 (ko) 2007-02-26
CZ2000490A3 (cs) 2000-08-16
DE1003781T1 (de) 2001-01-11
CN1243021C (zh) 2006-02-22
BRPI9811940A (pt) 2000-09-05
US7799541B2 (en) 2010-09-21
IL134523A0 (en) 2001-04-30
UA75862C2 (uk) 2006-06-15
US20100010200A1 (en) 2010-01-14
BRPI9811940B1 (pt) 2011-10-04
CA2298855A1 (en) 1999-02-25
ES2149149T1 (es) 2000-11-01
CZ300818B6 (cs) 2009-08-19
EP1003781B1 (en) 2009-09-23
WO1999009063A1 (en) 1999-02-25
CN1267307A (zh) 2000-09-20
CY1109664T1 (el) 2014-08-13
US20040037829A1 (en) 2004-02-26
DK1003781T3 (da) 2010-01-25
EP1003781A1 (en) 2000-05-31
PT1003781E (pt) 2009-10-26
AR062867A2 (es) 2008-12-10

Similar Documents

Publication Publication Date Title
NZ502392A (en) Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals
ATE544776T1 (de) Chimäre dna-bindeproteine
WO1999033982A3 (en) Human genes and gene expression products i
EP0832973A3 (en) GTP-binding protein
WO1999020756A3 (en) Human toll homologues
WO1999038972A9 (en) Human genes and gene expression products ii
IL110284A0 (en) Viral vectors and their use in gene therapy
HUT73962A (en) New bacillus thuringiensis strains and their insecticidal proteins
ATE394484T1 (de) Smad 6 und dessen anwendungen
AU8812498A (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
AU3477295A (en) Modified proteins
AU3186397A (en) Prion protein binding proteins and uses thereof
WO2001012660A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2001002563A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
EP0911409A3 (en) Deformylase
WO2001004297A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
EP1019500A4 (en) NEW IFN RECEPTOR 1 BINDING PROTEINS, ENCODING DNA AND METHOD FOR REGULATING THE CELLULAR RESPONSE TO INTERFERON
EP0885903A3 (en) Nucleic acid encoding streptococcus pheumoniae response regulator
WO1998007862A3 (en) Chemokine beta-16
EP0893501A3 (en) Ferrichrome transport atp-binding protein
EP0881292A3 (en) Streptocococcus pneumoniae peptide release factor
EP0899336A3 (en) Streptococcus pneumoniae spoIIIE protein
WO2001000824A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
EP0906957A3 (en) Lgt polypeptide
ECSP993285A (es) Sintesis recombinante de beta lipotropina y otros peptidos

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired